Cardlytics 10-Q: $29.9M Cash Against $194.7M Debt, Goodwill Impairment Risk Flagged
CDLX sits 39% above its 52-week low of $1.57.
Summary
Cardlytics' Q3 10-Q shows cash of $29.9 million against $194.7 million of total debt, a lender covenant waiver on 2026 Adjusted EBITDA, and a flagged risk of future goodwill impairment on its $110.3 million U.S. platform asset.
Key Events · Earnings and Guidance · CDLX
-
Q3 Revenue Falls 30% to $32.9M
Revenue dropped to $32.9 million from $47.0 million a year ago, and billings fell 32% to $57.2 million from $84.1 million. Monthly qualified users fell to 186.6 million from 230.3 million, driven by a U.S. FI partner exiting the platform.
-
Cash Thin Against $194.7M Debt Stack
Cash and equivalents were $29.9 million at September 30, 2026, down from $48.7 million at December 31, 2025. Total debt was $194.7 million: $169.7 million net carrying value of the 4.25% 2024 Convertible Senior Notes and $25.0 million drawn on the 2018 Line of Credit, with only $10.4 million of unused borrowing capacity.
-
Lender Loosens 2026 EBITDA Covenant
A Seventh Amendment to the 2018 Loan Facility dated October 30, 2026 resets the minimum cumulative Adjusted EBITDA for the 12 months ending December 31, 2026 to a floor of negative $6.0 million. The facility also requires minimum unrestricted cash of $20.0 million.
-
Goodwill Impairment Risk Flagged
The $110.3 million of goodwill on the U.S. Cardlytics Purchase Intelligence Platform passed a quantitative interim impairment test at September 30, 2026, but the filing states the unit has a heightened risk of future impairment given the sustained decline in stock price and market capitalization.
Analysis · CDLX · Technology
The Q3 numbers were already out this morning, but the full 10-Q reveals how thin the cushion has become. Cash fell to $29.9 million from $48.7 million at year-end, while total debt stands at $194.7 million — $169.7 million of convertible notes plus $25.0 million drawn on the revolver, leaving only $10.4 million of unused borrowing capacity. Management also disclosed a Seventh Amendment to its credit agreement, dated October 30, 2026, that lowers the minimum cumulative Adjusted EBITDA covenant for 2026 to a floor of negative $6.0 million — a lender concession that signals the business is running below the original plan. Separately, the $110.3 million of goodwill on the U.S. platform survived a quantitative impairment test at quarter-end, but management explicitly flags a heightened risk of future impairment given the sustained stock price decline. With revenue down 30% and monthly qualified users down 43.7 million year-over-year after a bank partner exit, the path to covering $172.5 million of notes maturing April 2029 depends on stabilizing the core platform.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDLX was trading at $2.19 on NASDAQ in the Technology sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.57 to $18.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.